Abstract
Several targeted agents have recently emerged for the treatment chronic lymphocytic leukemia and follicular lymphoma, which has made treatment selection more complex. Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®, described the growing therapeutic landscape of these diseases, as well as how to recognize and manage the toxicities commonly seen with targeted agents.
